Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Triclabendazole has been used in trials studying Parasitic Disease.
Description | Triclabendazole has been used in trials studying Parasitic Disease. |
In vitro | Triclabendazole treatment produces percentage decreases of the fluke egg output by 15.3%, 4.3% and 36.6%, respectively, in sheep, dairy cows and heifers, these results indicate the presence of TCBZ-resistant Fasciola hepatica in sheep and cattle on this farm. [1] Triclabendazole sulphoxide (50 mg/mL) results in extensive damage to the tegument of triclabendazole-susceptible F. hepatica, whereas triclabendazole-resistant flukes shows only localized and relatively minor disruption of the tegument covering the spines. [2] |
Synonyms | CGA89317 |
Molecular Weight | 359.66 |
Formula | C14H9Cl3N2OS |
CAS No. | 68786-66-3 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 67 mg/mL (186.3 mM)
H2O: <1 mg/mL
Ethanol: <1 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Triclabendazole 68786-66-3 Cytoskeletal Signaling Microbiology/Virology Parasite Microtubule Associated CGA 89317 CGA89317 Inhibitor Microtubule/Tubulin inhibit CGA-89317 inhibitor